[Use of divascan in the treatment of diabetic retinopathy].
Divascan (iprasochrome), a drug designed by GDR pharmacologists, brings about a positive effect in the management of diabetic microangiopathies, particularly at early stages. Altogether 22 patients with diabetes mellitus, types I and II, were on divascan therapy. Before and after treatment the patients were subjected to clinical and ophthalmoscopic studies including the determination of microcirculation in the conjunctiva, renal function, the level of serotonin, its precursors and the main metabolite. The optimal dose of divascan is 7.5-10 mg/day, the period of therapy not less than 3 months followed by the use of maintenance doses. The drug produces no side effects.
D000323:Adrenochrome / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D002199:Capillary Permeability / Q000187:drug effects; D002986:Clinical Trials as Topic; D003228:Conjunctiva / Q000098:blood supply; D003922:Diabetes Mellitus, Type 1 / Q000150:complications; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D045563:Indolequinones; D008833:Microcirculation / Q000187:drug effects; D008875:Middle Aged
D045563:Indolequinones; D000323:Adrenochrome; C009742:iprazochrome
Primenenie divakana v lechenii diabeticheskoĭ retinopatii.